Category Archives: CD123

AstraZeneca and Cellectis Enter into Collaboration to Develop up to 10 Novel Cell and Gene Therapy Candidates Leveraging Cellectis’s Gene Editing Technologies and Manufacturing Capabilities

On Wednesday, November 1, AstraZeneca (press release) and Cellectis (press release) announced they entered into a strategic collaboration and investment agreement for the development of up to 10 novel cell and gene therapy candidate products in areas of high unmet need, including oncology, immunology, and rare diseases. Below, Celltelligence provides insights on the partnership, analyzes Cellectis’s TALEN-based gene-editing platform, and discusses how both companies could benefit from the collaboration.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

CB-012’s IND Cleared by the FDA; Caribou Joins the AML Race

On Wednesday, October 18, Caribou announced CB-012’s (allogeneic CLL-1 CAR-T; PD-1 KO + B2M KO + TCR KO + B2M-HLA-E KI) IND clearance by the FDA to start a trial in 2-4L AML. Below, Celltelligence provides insights on the trial design while discussing the potential advantages of Caribou’s AML program over its competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellectis to Deprioritize its Multiple Myeloma Program; All Ongoing Trials to Include Sanofi’s Alemtuzumab as Lymphodepleting Agent; Cellectis’s Q1 2023 Earnings Call Summary

On Friday, May 5, Cellectis held its Q1 2023 earnings call (press release) highlighting the company’s decision to deprioritize the clinical development of UCARTCS1 (allogeneic CS1 CAR-T) in multiple myeloma to focus on the advancement of the rest of its pipeline. Below, Celltelligence provides insight on Cellectis’s decision to stop investing in its MM program, while discussing the implementation of Sanofi’s alemtuzumab (anti-CD52 mAb) across all its trials.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Caribou, AvenCell and Amgen Report Preclinical Data in AML; AACR 2023 Analysis 4

AACR 2023 Analysis 4: Caribou, AvenCell, and Amgen presented preclinical data from their cell therapies in AML. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Arcellx and Gilead Focus on Accelerating CART-ddBCMA Clinical Development, Initiation of ACLX-002’s Ph1 trial in AML; Arcellx Q4 2022 Earnings Summary

On Wednesday, March 29, Arcellx provided its Q4 and FY 2022 financial results and business updates (press release) highlighting its strategic collaboration with Gilead (Kite) to co-develop and co-commercialize CART-ddBCMA (autologous BCMA CAR-T) for the treatment of ≥4L MM announced on December 9, 2022. Additionally, the company noted the initiation of ACLX-002’s (Universal ARC-T cells + CD123 targeting SparX protein) Ph1 trial in r/r AML and HR-MDS in December 2022. Below, Celltelligence provides insights on Arcellx’s strategic decision to partner with Gilead (Kite), while discussing ARC-SparX platform.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

You May Have Missed: ASH 2022 Analyses

During ASH 2022, the Celltelligence team published an eight-part series analyzing the latest cell therapy-related clinical updates:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Updated Results from CART-ddBCMA in R/R MM; Could Gilead Take an Interest in the ARC-SparX Platform? Arcellx Meets Clinical Milestones; ASH 2022 Arcellx Investor Event

On Sunday, December 11, Arcellx held an ASH investor event (presentation) highlighting updated clinical data from CART-ddBCMA’s (autologous BCMA CAR-T) Ph1 trial in patients with r/r MM. Moreover, management provided further details on their recently signed collaboration with Gilead (Kite). Below, Celltelligence provides insights on CART-ddBCMA’s potential best-in-class profile while discussing how Gilead’s collaboration could impact the MM space in the long-term.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

UCART20x22 Receives FDA IND Clearance; Novel Universal CAR-T Program; No Clinical Milestone Updates for UCART22, UCART123, or UCARTCS1; Cellectis’s Q2 2022 Earnings Call Summary

On Friday, August 5, Cellectis held their Q2 2022 earnings call (press release) highlighting UCART20x22’s (allogeneic CD20xCD22 dual CAR-T) FDA IND clearance for r/r NHL. Of note, no major clinical updates were provided for allogeneic therapies UCART22 (CD22 CAR-T), UCART123 (CD123 CAR-T) or UCARTCS1 (CS1 CAR-T). Below, Celltelligence provides insights on Cellectis’s FDA IND clearance and pipeline development.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Kymriah’s Sales Decline; PHE885 Pivotal Study Initiated; YTB323’s Anticipated Submission Delayed to 2025; Novartis’s Q1 2022 Earnings Call Summary

On Tuesday, April 26, 2022, Novartis held their Q1 2022 earnings call (press release / presentation) highlighting a decline in Kymriah’s (CD19 CAR-T) sales. Additionally, management noted Kymriah’s positive CHMP opinion in ≥3L FL, PHE885’s (T-Charge BCMA CAR-T) Ph2 trial initiation in 4L MM, and YTB323’s (T-Charge CD19 CAR-T) delayed regulatory filing in 2L DLBCL. Below, Celltelligence provides insights on Kymriah’s Q1 2022 revenue, while discussing YTB323’s delayed submission.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellectis’s Raleigh GMP Facility is Fully Operational; Cellectis to Prioritize Clinical Programs During 2022; Solid Tumor Programs Deprioritized in 2022; Cellectis Q4 2021 Earnings Call Summary

On Friday, March 4, Cellectis held their Q4 2021 earnings call (press release) highlighting their ongoing clinical trials and UCART20x22 (allogeneic CD20 x CD22 dual CAR-T) asset. Furthermore, Cellectis confirmed that their GMP facility in Raleigh, NC, is now fully operational. Below, Celltelligence provides insights on Cellectis’s decision to deprioritize their solid tumor programs, while discussing their in-house manufacturing strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.